Lantheus Holdings, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Overall research band Above average

Quality Strong

Valuation Above average

Balance sheet Mixed

Market confirmation Mixed

One-minute company read

What this report can tell you now

What the company does

Lantheus Holdings, Inc. is a global pharmaceutical company based in North Billerica, Massachusetts, focused on developing, manufacturing, and commercializing advanced diagnostic and therapeutic agents. Its main products include DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator for nuclear medicine; Xenon-133 for pulmonary function assessment; Neurolite for identifying stroke-damaged brain areas; Cardiolite and Thallium-201 for cardiovascular imaging; Gallium-67 for infection and tumor detection; the Automated Bone Scan Index for quantifying prostate cancer burden; PYLARIFY for detecting recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In therapeutics, Lantheus offers AZEDRA for radiopharmaceutical treatment and RELISTOR for opioid-induced constipation. The company’s development pipeline includes agents for myocardial blood flow, PSMA-targeted therapies, neuroblastoma imaging, AI-powered prostate cancer analysis, and investigational monoclonal antibodies.

The current research profile is Market-Leading Quality, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC21.6%Model input; read with the evidence status and period context.

Operating margin20.2%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years38.0%Model input; read with the evidence status and period context.

FCF margin23.0%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.